IMMUNE SYSTEM DISEASES

This early-phase study tests a new treatment for people with multiple myeloma that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack myeloma cells carrying a protein call…

This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other therapies. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells carrying a protein …

This early-phase study tests a new treatment for people with certain types of lymphoma that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells, plus a…

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The T-cells are modified to target cancer cells and include a safety switch that can be turned on to reduce severe side effects. The goa…

This study tests a new treatment called PVX108 for children and teens with peanut allergies. The goal is to see if it is safe and helps them tolerate more peanut protein without a reaction. About 90 participants will receive either the treatment or a placebo, and their peanut tol…

This study tests whether a stem cell transplant from a healthy donor can safely give people with severe T-cell problems a new, working immune system. About 71 participants aged 4 and older will receive chemotherapy and antibody therapy before the transplant, then be followed for …

This study tests a new treatment for people with a hard-to-treat type of leukemia. The treatment uses the patient's own immune cells (T cells) that are modified to better find and kill cancer cells. A safety switch is added to turn the cells off if severe side effects occur. The …

This study was designed to test an experimental drug called HMPL-523 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The goal was to see if the drug is safe and can raise platelet counts. However, th…

This study collects medical information and biological samples from 32 cancer patients starting or restarting immunotherapy. The goal is to better understand why some patients develop immune-related side effects and how to manage them. Researchers hope this knowledge will improve…